Board of Directors

Brenda Andrews, PhD 
University Professor C.C., FRSC
Charles H. Best Chair of Medical Research
University of Toronto

Brenda Andrews is the Charles H. Best Chair of Medical Research, Director of the Donnelly Centre for Cellular and Biomolecular Research and Professor of Molecular Genetics at the University of Toronto.

Dr. Andrews completed her PhD in Medical Biophysics (with Paul Sadowski) at the University of Toronto, and postdoctoral training in genetics with the late Dr. Ira Herskowitz at the University of California San Francisco.

In 1991, Dr. Andrews was recruited to the Department of Medical Genetics (now Molecular Genetics) at the University of Toronto. She became Chair of the Department in 1999, a position she held for 5 years before assuming a position as Chair of the Banting & Best Department of Medical Research and as the inaugural Director of the Donnelly Centre. Dr. Andrews’ current research interests include analysis of genetic interaction networks in budding yeast and mammalian cells, using high through-put genetics platforms that include high content microscopy for systematic analysis of cell biological phenotypes. Dr. Andrews is a Companion of the Order of Canada, an elected Fellow of the Royal Society of Canada, the American Association for the Advancement of Science and the American Academy of Microbiology. She joined the BWF Board in October 2019.

Emery N. Brown, MD, PhD
Warren M. Zapol Professor of Anaesthesia
Harvard Medical School/Massachusetts General Hospital

Edward Hood Taplin Professor of Medical Engineering and Computational Neuroscience
Massachusetts Institute of Technology

Dr. Brown received his B.A. (magna cum laude) in Applied Mathematics from Harvard College, his M.A. in statistics from Harvard University, his M.D. (magna cum laude) from Harvard Medical School and a Ph.D. in statistics from Harvard University. He is an anesthesiologist-statistician whose methodology research develops signal processing algorithms to characterize how the brain represents and transmits information. His experimental research is to define how anesthetic drugs act in the brain to create the state of general anesthesia.  [Read more]

 

John E. Burris, PhD
President
Burroughs Wellcome Fund

John E. Burris became president of the Burroughs Wellcome Fund in July 2008.  He is the former president of Beloit College. Prior to his appointment at Beloit in 2000, Dr. Burris served for eight years as director and CEO of the Marine Biological Laboratory (MBL) in Woods Hole, Mass. From 1984 to 1992 he was at the National Research Council/National Academies where he served as the executive director of the Commission on Life Sciences.

A native of Wisconsin, he received an A.B. in biology from Harvard University in 1971, attended the University of Wisconsin-Madison in an M.D.-Ph.D. program, and received a Ph.D. in marine biology from the Scripps Institution of Oceanography at the University of California-San Diego in 1976. A professor of biology at the Pennsylvania State University from 1976 to 1985, he held an adjunct appointment there until coming to Beloit.  His research interests were in the areas of marine and terrestrial plant physiology and ecology.

He has served as president of the American Institute of Biological Sciences and is or has been a member of a number of distinguished scientific boards and advisory committees including the Grass Foundation, the Stazione Zoologica “Anton Dohrn” in Naples, Italy, the American Association for the Advancement of Science, and the Radiation Effects Research Foundation in Hiroshima, Japan. He has also served as a consultant to the National Conference of Catholic Bishops' Committee on Science and Human Values.

 

Terence S. Dermody, MD
Vira I. Heinz Professor and Chair of Pediatrics
Professor of Microbiology and Molecular Genetics
University of Pittsburgh School of Medicine
Physician-in-Chief and Scientific Director
Children’s Hospital of Pittsburgh of UPMC

Dr. Terence S. Dermody is the Vira I. Heinz Professor and Chair of Pediatrics at the University of Pittsburgh School of Medicine and Physician-in-Chief and Scientific Director at Children’s Hospital of Pittsburgh of UPMC. He also is Professor of Microbiology and Molecular Genetics at the University of Pittsburgh School of Medicine. [Read more]
 

Brian Druker, MD
Director, Knight Cancer Institute at Oregon Health & Science University
JELD-WEN Chair of Leukemia Research
Investigator, Howard Hughes Medical Institute

Brian Druker, MD, revolutionized the treatment of cancer through research that resulted in the first drug to target the molecular defect of cancer while leaving healthy cells unharmed. Marketed under the name Gleevec®, his discovery turned a once-fatal cancer, chronic myeloid leukemia, into a manageable condition. [Read more]
 

Wendell Lim, PhD
Professor and chair, Department of Cellular and Molecular Pharmacology
University of California - San Francisco
Howard Hughes Medical Institute Investigator
director, UCSF Center for Systems & Synthetic Biology

Wendell Lim, PhD, is interested in understanding how genetically encoded molecular programs can yield the remarkable behaviors observed in biological organisms, at multiple scales. He received his undergraduate degree at Harvard University and a doctoral degree at MIT, as well as completing a postdoctoral fellowship at Yale University. Now chair and professor of cellular and molecular pharmacology at UC San Francisco, Lim began his research career as a biophysical chemist and structural biologist studying problems such as the evolutionary optimization of enzymes, how protein structure is encoded in sequence, and the determinants of protein-protein interaction specificity. His research has gradually shifted towards utilizing this mechanistic understanding of molecules as a foundation to study how systems of interacting molecules assemble to yield cellular or organismal signaling behaviors – complex behaviors in both space and time. His lab is interested in both the fundamental principles governing these molecular programs, as well as the way such programs have evolved. How to identify the most relevant functional modules at various scales of biology is an ongoing but fascinating challenge. We have also become interested in using synthetic biology and our growing understanding of molecular networks to engineer cells with novel behaviors, such as therapeutic immune cells programmed to recognize and treat cancer or other diseases. A Howard Hughes Medical Institute Investigator, Lim is director of the UCSF Center for Systems and Synthetic Biology and is the scientific founder of Cell Design Labs, a company pioneering advanced cell therapies.  Dr. Lim joined the Burroughs Wellcome Fund Board of Directors in October 2018.

Kelsey Martin, MD, PhD (Chair)
Dean for the David Geffen School of Medicine
Professor of Biological Chemistry and Psychiatry and Biobehavioral Sciences
University of California-Los Angeles

Dr. Kelsey Martin is the Dean for the David Geffen School of Medicine at UCLA and a Professor in the Departments of Biological Chemistry and Psychiatry and Biobehavioral Sciences. Outside UCLA, In addition to being a Senior Fellow at the Howard Hughes Medical Institute Janelia Research Campus, Dr. Martin serves on the editorial board of Cell, the board of directors for the Burroughs Wellcome Fund, the selection committee of the McKnight Scholar Awards and the board of directors of the McKnight Endowment Fund for Neuroscience. Dr. Martin served as co-director of the UCLA-Caltech Medical Scientist Training Program from 2005-2013, Chair of the Department of Biological Chemistry from 2010-2015, Chair of the Neuroscience Research Theme Committee from 2013-2015 and Chair of the David Geffen School of Medicine Basic Science Chairs from 2012-2015. She was named Executive Vice Dean and Associate Vice Chancellor at the Geffen School of Medicine. [Read more]

Lauretta (Retz) Reeves, CFA, AWMA
Partner
International Portfolio Manager

Islamorada Investment Management

Retz Reeves is the international equities portfolio manager at Islamorada Investment Management (IIM) and utilizes a value-based approach.  Ms. Reeves joined IIM in 2013. She has served as a portfolio manager and Co-Chief Investment Officer of the Value Strategy at Hansberger Global Investors (HGI).  Before HGI, Ms. Reeves was a portfolio manager and Senior Vice President with Franklin Templeton Investments.  She is a CFA® Charter Holder and a member of the CFA Institute and The CFA Society of South Florida.  Also, she holds the designation of Accredited Wealth Management Advisor (SM) (“AWMA”) from the College of Financial Planning.  She received a BBA from Florida International University with High Honors and an MBA from Nova Southeastern University.  She is a member of the Baptist Hospital Foundation Founders’ society and the Upper Keys Century Business and Professional Women. Ms. Reeves also serves as a mentor for Take Stock in Children.

Christine Seidman, MD
T.W. Smith Professor of Medicine & Genetics
Investigator of Howard Hughes Medical Institute
Director, Brigham & Women's Cardiovascular Genetics Center

Christine Seidman, MD is the Thomas W. Smith Professor of Medicine and Genetics at Harvard Medical School and Brigham and Women’s Hospital. She is an Investigator of the Howard Hughes Medical Institute.  She was an undergraduate at Harvard College and received a M.D. from George Washington University School of Medicine.  After clinical training in Internal Medicine at John Hopkins Hospital Seidman received subspecialty training in cardiology at the Massachusetts General Hospital.

Seidman practices at the Brigham and Women’s Hospital, where she is the founding Director of the BWH Cardiovascular Genetics Center. Composed of a multidisciplinary team of physicians and scientists, the BWH Cardiovascular Genetics Center provides unparalleled care to patients with cardiomyopathies and their families.  Through her translation of basic science discoveries, the BWH Cardiovascular Genetics Center has transformed the clinical diagnosis and management of cardiomyopathies and is defining innovative treatment strategies.

Seidman directs a basic research program that focuses on the discovery of genes, mutations, and mechanisms for human heart muscle disorders, particularly cardiomyopathies and congenital heart defects.  Translation of these fundamental discoveries has enabled gene-based diagnosis and novel therapeutic targets.  Her accomplishments have garnered many honors, including the Fondation Lefoulon-Delande Le Grande Prix for Cardiovascular Research awarded by the Academie de Science, - Institut de France, Distinguished Scientist Award of the American Heart Association, Fellow of the American Academy of Arts and Sciences, and membership in the National Academy of Medicine and the National Academy of Sciences.  Dr. Seidman is also a former president of the Association of American Physicians.
 

Jenny Ting, PhD
William Rand Kenan Professor of Genetics
Immunology Program Leader, Lineberger Comprehensive Cancer Center
Director, UNC Center for Translational Immunology
Co-Director, Institute of Inflammatory Disease
University of North Carolina-Chapel Hill

Dr. Jenny Ting received her Ph.D. in Microbiology and Immunology from Northwestern University in Chicago, IL and postdoctoral training at the University of Southern California and Duke University.  She joined the faculty at the University of North Carolina, Chapel Hill as an Assistant Professor and has been there since that time.  Currently, she is a William Rand Kenan Professor of Genetics and the UNC Lineberger Comprehensive Cancer Center’s Immunology Program Leader. She is also the Director of the UNC Center for Translational Immunology and the co-Director of the Institute of Inflammatory Diseases.

From 2008 to 2014, she served as the co-Director of the Southeast Regional Center for Excellence in Emerging Infections and Biodefense (SERCEB).  She is currently the Program Director of an NIAID-funded Center for Translational Research, NIAID-funded Center for Immune-mediated Viral Control, a National Multiple Sclerosis Society (NMSS) funded Collaborative Multiple Sclerosis Center and an NIH training grant. She has trained more than 90 postdoctoral fellows and students who have gone on to successful scientific careers ranging from deanship, chairmanship, professors and industrial leaders.  

Nationally, Dr. Ting has served on multiple NIH advisory boards, as well as committees for the NMSS, Burroughs Wellcome Fund, and American Asthma Foundation. She has been awarded the American Society of Microbiology Award for Outstanding Contributions to the Field of Immunology and Immunity and selected as the 2013 American Association of Immunology prestigious Life Technologies Awardee. She is an elected member of the Academia Sinica in Taiwan and the American Association of Immunologists council.

She has pioneered new areas of innate immunity, most notably reporting the first study describing the entire human NOD-like receptor family and continued to be a leader in this field.  Her work combines fundamental innate immunology with molecular biology and she has reported extensively on the impact of innate immunity in infection, autoimmunity, cancer, microbiome composition and metabolic disorders. She has published over 280 articles, many in top journals.  She joined the Fund's Board of Directors in February 2017.

Honorary Board Member
 

Philip R. Tracy
Of Counsel
Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.

Mr. Tracy received his undergraduate degree from the University of Nebraska and law degree from George Washington University. He joined Burroughs Wellcome Co. in 1974 as assistant general counsel, and he served as the company's president and the chief executive officer from 1989 until its sale to Glaxo in 1995. Mr. Tracy currently is associated with the North Carolina-based law firm of Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. and is a Venture Partner with InterSouth Partners, an early stage Venture Fund located in Durham, North Carolina. He serves on the board of directors of several companies and non-profit organizations. Mr. Tracy served on the BWF board from 1989-1996 and again from 2001-2008.